Pfizer and how it could double

I am maintaining a positive risk/reward rating on Pfizer (NYSE: PFE) based on its aggressive growth strategy, rapidly increasing growth estimates, a deeply discounted valuation, and unusually strong technical support.

Risk/Reward Rating: Positive

If someone had asked me prior to 2021 to estimate the probability of Pfizer growing its sales by 140% over two years, my estimate would have been exceedingly close to 0%. That Pfizer accomplished this is testament to the sheer scale of the biotechnology opportunity set. It is also renders the growth potential self-evident.